Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the United States. It markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. The company's lead product include DEXTENZA, which is in Phase III clinical trial for the treatment of post-surgical ocular inflammation and pain during cataract surgery, as well as for the treatment of allergic conjunctivitis; and in Phase II clinical trial for the treatment of inflammatory dry eye disease. It is also developing OTX-TP, which has completed Phase IIb clinical trial for glaucoma and ocular hypertension. In addition, the company has a pipeline of earlier stage punctum plug product candidates, including OTX-MP, which has completed a Phase I clinical trial evaluating safety and pharmacokinetics in patients during cataract surgery; and evaluates sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.
Ocular Therapeutix (OCL) Stock Soars, FDA: Corrective Actions Address Concerns NEW YORK (TheStreet) -- Shares of Ocular Therapeutix (OCUL) were rising 31.19% to $5.51 on heavy trading volume early Thursday afternoon after the Food and Drug Administration released a note saying the company's corrective actions on its new drug application for Dextenza have addressed the agency's concern. Over 4.18 million shares of the Bedford, MA-based biopharmaceutical company have traded so far today, well above its 30-day daily average of 504,000 shares.
Analyst Upgrade/Downgrade Update Brokerage firm: RBC Capital Mkts Change: Coverage Reiterated/Price Target Changed Previous Rating: N/A Current Rating: Outperform Previous Price Target: $30 Current Price Target: $32
The resistance levels from my last chart held perfectly, now if $9 holds, remain bullish in the short term.
Ocular Therapeutix™ Announces Additional Successful Results for Phase 3 Clinical Trial of DEXTENZA http://finance.yahoo.com/news/ocular-therapeutix-announces-additional-successful-130000823.html
Ocular TherapeutixTM to Present at Three Upcoming Investor Conferences EDFORD, Mass.--(BUSINESS WIRE)-- 2017 BIO CEO & Investor Conference Monday, February 13, 2017 at 8:30 a.m. Eastern Time The Waldorf Astoria New York, New York, NY 2017 RBC Capital Markets Global Healthcare Conference Thursday, February 23, 2017 at 9:00 a.m. Eastern Time The New York Palace Hotel, New York, NY 37th Annual Cowen and Company Healthcare Conference Monday, March 6, 2017 at 2:40 p.m. Eastern Time The Boston Marriott Copley Place, Boston, MA
$OCUL wow. missed all this. A lot of carnage around $9.75 from stop losses. Trying to figure out the next step!
